Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics
Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Joan Bladé(Hospital Clínic de Barcelona), Jesús F. San Miguel(Clinica Universidad de Navarra), María‐Victoria Mateos(Hospital Clínico San Carlos), Javier de la Rubia(Universitat de València), Adrían Alegre(Hospital Universitario de La Princesa), Norma C. Gutiérrez(Universidad de Salamanca), Helgi van de Velde(Sanofi (Belgium)), Albert Oriol(Institut Català d'Oncologia), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Xiangyang Liu(Shandong University of Traditional Chinese Medicine), Carlos Pisón Herrero(Johnson & Johnson (United States)), Pedro García-Sánchez(Hospital Clínico San Carlos), Juan José Lahuerta(Research Institute Hospital 12 de Octubre)
Cited by 111
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k